#USA #Louisville #Cognision #SOMNOmedics #Sleep Biomarkers

Cognision Partners with SOMNOmedics to Elevate Drug Development

Cognision, a frontrunner in neurophysiological biomarker solutions, has recently forged a strategic alliance with SOMNOmedics AG, a recognized leader in advanced sleep diagnostics technology. This partnership is set to significantly enhance the quality of sleep biomarker data available for pharmaceutical clinical trials, particularly as the industry places a greater emphasis on understanding the role of sleep in drug efficacy and safety.

The collaboration will leverage Cognision’s expertise in delivering complex neurophysiological assessments tailored for regulated research environments alongside SOMNOmedics' innovative polysomnography (PSG) technology, which is compact and mobile. The integration of these two capabilities promises to offer sponsors a comprehensive solution for capturing precise and reliable data on sleep architecture—critical in trials investigating drugs for sleep disorders or those affecting sleep patterns.

“Sleep endpoints have emerged as pivotal in Central Nervous System (CNS) drug development, impacting areas from neurodegenerative diseases to pain management and even novel psychedelic therapies,” states Dr. Igor Korolev, VP of Neuroscience and Digital Health at Cognision. He emphasizes that this partnership will deliver state-of-the-art PSG solutions coupled with streamlined deployment and centralized data management, enabling highly reproducible automated analysis, while mitigating the complexities and delays often associated with CNS biomarker trials.

Modernizing Clinical Trials for Better Outcomes

SOMNOmedics’ PSG systems are globally recognized for their exceptional signal quality and adaptability, making them suitable for both inpatient settings and decentralized trials. The dual advantage of portability and sophistication allows researchers to gather essential sleep data without compromising on accuracy. All PSG data will be processed within Cognision’s regulatory-compliant cloud-based Clinical Trial Data Management System (CTMS), granting sponsors immediate access to data for swift decision-making and facilitating adaptive trial designs.

Denise Frahley, Director of US Sales at SOMNOmedics, highlights, “This partnership extends beyond just providing equipment. It’s about ensuring that each site, patient, and data point adheres to the highest industry standards.” With their combined operational and technical innovations, Cognision and SOMNOmedics aim to redefine sleep measurement practices within pharmaceutical research, establishing a new benchmark in the industry.

The Future of Biomarker-Driven Drug Development

Cognision's standing as a premier partner for neurophysiological endpoints in drug development is reinforced through this partnership. The company possesses an in-depth understanding of protocol design, site enablement, data management, and analytics—essential components for maintaining data quality across diverse pharmaceutical trials. On the other hand, SOMNOmedics will expand its advanced sleep diagnostics technology into the pharmaceutical trial sector, supporting researchers in their quest for biomarker-driven precision-targeted drug development.

Both companies are excited about the potential outcomes this partnership will yield, noting that improved sleep biomarkers could pave the way for breakthroughs in drug therapies across various CNS-related conditions. Clinical research is on the verge of a transformation that integrates meticulous biomarker analysis into routine practice, providing richer insights into how medications affect not just health but the holistic well-being of patients.

About Cognision

Cognision focuses on providing comprehensive neurophysiological measurement services for clinical trials. The company is known for its expertise in EEG, ERP, and cognitive testing, ensuring consistency and compliance across various pharmaceutical studies.

About SOMNOmedics AG

SOMNOmedics specializes in developing portable and stationary sleep diagnostic systems, renowned for their quality and flexibility. They aid clinicians and researchers in capturing high-quality sleep data crucial for patient care and clinical research.

For additional information and media inquiries, contact Nathan Alvarado at 502-561-7005 or via email at [email protected]